Beckley Psytech fetches $80m Series B

Beckley Psytech, a UK-based developer of psychedelic medicines, has raised $80 million in Series B financing.

17 August 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles